Compare ResMed Inc. (RMD) vs iShares 1 3 Year Treasury Bond ETF (SHY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs iShares 1 3 Year Treasury Bond ETF — how do they compare? ResMed Inc. trades at $230.12 (market cap $31.89B), while iShares 1 3 Year Treasury Bond ETF trades at $81.19 (market cap $26.68B). The key difference: ResMed Inc. is the larger of the two by market cap, and ResMed Inc. pays a 1.16% dividend while iShares 1 3 Year Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and iShares 1 3 Year Treasury Bond ETF for 63 Days on average.
| RMD | SHY | |
|---|---|---|
Market Cap | $31.89B | $26.68B |
Volume | 618,314 | 4,077,691 |
Sector | Health | Fixed Income |
52-Week High | $277.88 | $83.18 |
52-Week Low | $182.82 | $81.05 |
Typical Hold Time | 51 Days | 63 Days |
Enterprise Value | $31.24B | — |
Dividend Yield | 1.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $230.91, up 2.18% today, with a bullish technical signal and strong fundamentals. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $2.68. Revenue grew to $5.15B in 2025, with a net income margin of 26.94%. Analyst consensus is a buy, with a $242.70 price target. Recent news highlights EPS growth targets of 12%-14% and participation in investor conferences.
Outlook is positive due to robust earnings growth and market share gains, but risks include competitive pressures and regulatory investigations. The stock offers upside to the consensus target, supported by institutional buying and solid cash flow generation.
SHY trades at $81.185 with minimal daily movement (+0.03%), reflecting stability amid broader bond market volatility. The technical picture shows a bearish trend with moving averages signaling caution, while oscillators remain neutral. Recent dividend payments of $0.24-$0.25 demonstrate consistent income distribution. The fund operates in a challenging environment with rising Treasury yields impacting bond valuations.
SHY faces headwinds from the ongoing bond market selloff and rising interest rates, which pressure short-term bond ETFs. However, the fund's structure provides relative stability compared to longer-duration instruments. The primary risk remains further Fed tightening, while the opportunity lies in capital preservation during market turbulence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About iShares 1 3 Year Treasury Bond ETF
SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →
